Evidence map›Paper›PMID 39551718›Full record

ArticleBritish journal of haematology2024

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.

Hayley Colton, Natalie Barratt, Nigel Temperton, Hailey Hornsby, Adrienn Angyal, Irina Grouneva, Benjamin B Lindsey, Pamela Kearns, Eleanor Barnes, Carl S Goodyear and 28 more

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Hayley ColtonDivision of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.ORCID https://orcid.org/0000-0002-3287-4103
Natalie BarrattDivision of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.
Nigel TempertonViral Pseudotype Unit, Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham, UK.
Hailey HornsbyDivision of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.
Adrienn AngyalDivision of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.
Irina GrounevaDivision of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.
Benjamin B LindseyDivision of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.
Pamela KearnsCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0003-2756-5813
Eleanor BarnesPeter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Carl S GoodyearCollege of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Alex RichterClinical Immunology Service, University of Birmingham, Birmingham, UK.
David ThomasThe Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), University of Cambridge, Cambridge, UK.
Gordon CookNational Institute for Health Research, Leeds MIC, University of Leeds, Leeds, UK.
Iain B McInnesCollege of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Michelle WillicombeDepartment of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, UK.
Stefan SiebertCollege of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
Kim OrchardDepartment of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Rachael SelbySheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK.
Sarah BowdenCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, UK.
Paul J ColliniDivision of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.
Ann PopeCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, UK.
Amanda KirkhamCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, UK.
Barbara KronsteinerPeter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Susanna J DunachiePeter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Paul MillerBritish Society of Blood and Marrow Transplantation and Cellular Therapy, Guy's Hospital, London, UK.ORCID https://orcid.org/0000-0002-4357-4392
Jennifer ClayDepartment of Haematology, St James's University Hospital, Leeds, UK.
Erin HurstNorthern Centre for Cancer Care, Freeman Hospital, Newcastle, UK.
Ram MalladiDepartment of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Murali KesavanDepartment of Oncology, Cancer and Haematology Centre, Churchill Hospital, Oxford, UK.
Francesca KinsellaCentre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Robin SandersonKing's College Hospital NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0003-4915-2833
Kwee L YongDepartment of Haematology, Cancer Institute, University College London, London, UK.
Daniel ReaCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, UK.
Helen ParryCentre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
PITCH Consortium, OCTAVE Collaborative Group, OCTAVE‐DUO Investigators, PROSECO Investigators
Sean H LimCentre for Cancer Immunology, University of Southampton, Southampton, UK.
John A SnowdenDivision of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.ORCID https://orcid.org/0000-0001-6819-3476
Thushan I de SilvaDivision of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.

Funding

Blood Cancer UK 21023British Society for Haematology 21009Cancer Research UK A25141Cancer Research UK A27179Cancer Research UK C22436/A25354Huo Family FoundationIMPACT consortiumMedical Research Council MR/X009297/1National Institute for Health and Care Research COV19-RECPLASNIHR Southampton Biomedical Research CenterNIHR Southampton Clinical Research FacilitySheffield Teaching Hospitals NHS Foundation TrustThe Danson Foundation DAN581929UK Government Vaccine Task ForceUniversity of Birmingham
6 · The paper itself

Abstract

Whilst SARS-CoV-2 mRNA vaccines generate high neutralising antibodies (nAb) in most individuals, haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T-cell (CAR-T) recipients respond poorly. HSCT/CAR-T treatment ablates existing immune memory, with recipients requiring revaccination analogous to being vaccine naive. An optimal revaccination strategy for this cohort has not been defined. Factors predicting immunogenicity following three ancestral SARS-CoV-2 vaccines were assessed in 198 HSCT/CAR-T recipients and 96 healthcare workers (HCWs) recruited to multicentre studies. Only 25% of HSCT/CAR-T recipients generated nAbs following one dose, with titres 167-fold and 7-fold lower than that in HCWs after the first and second doses, respectively. Lower post-second dose nAb titres were associated with older age, rituximab use, and previous HSCT. ChAdOx1-S recipients were more likely to generate nAbs compared with mRNA vaccines, with titres comparable to HCWs. In contrast, nAbs were significantly lower in HSCT/CAR-T recipients than HCWs after mRNA vaccination. The poor first-dose immunogenicity in HSCT/CAR-T recipients suggests a minimum licensed dosing interval could limit the period of vulnerability following HSCT/CAR-T. The relative preservation of nAbs with ChAdOx1-S vaccination highlights the importance of evaluating alternative platforms to mRNA vaccination within this highly vulnerable clinical cohort.

Indexed as

Antibodies, NeutralizingAntibodies, ViralChAdOx1 nCoV-19COVID-19Hematopoietic Stem Cell TransplantationSARS-CoV-2AdultAgedCOVID-19 VaccinesFemaleHumansImmunization, SecondaryImmunogenicity, VaccineMaleMiddle AgedmRNA VaccinesAntibodies, NeutralizingAntibodies, ViralChAdOx1 nCoV-19COVID-19 VaccinesmRNA VaccinesSARS‐CoV‐2stem cell transplantvaccination

Identifiers

PMID39551718
PMCPMC11637739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.